NeoStem is pursuing a development program relating to its VSEL™ Technology in selected clinical applications and markets based on unmet medical need, target patient population size, regulatory strategy, and overall commercial market. Through both grant funding and NeoStem's own funding, the Company is exploring the potential of VSEL™ Technology in the treatment of periodontitis, healing complex skin and soft tissue wounds, corneal regeneration and repair, age-related macular degeneration, nerve regeneration and acute radiation syndrome in a parallel but staggered timeline. NeoStem anticipates that a single clinical manufacturing process will be developed for these indications, collectively, and that the major pacing item will be the generation of preclinical data to support the filing of an investigational new drug application (IND) for a Phase 1 clinical trial, the first of which it expects to be in periodontitis.
The event takes place at the Radisson SAS Hotel, Szczecin, Poland and is organized by Pomeranian Medical University.
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.For more information, please visit: www.neostem.com . About VSEL™ Technology Mariusz Ratajczak, M.D., Ph.D., head of the Stem Cell Biology Program at the James Graham Brown Cancer Center at the University of Louisville, discovered that mammalian bone marrow contains a heterogeneous population of stem cells that has properties similar to those of embryonic stem cells. These cells, first described in mice, are referred to as very small embryonic-like (VSEL) stem cells, and the technology is referred to as VSEL™ Technology. NeoStem is engaged in research and development of new therapies based on VSEL™ Technology and pursuant to its license agreement with the University of Louisville, NeoStem has the exclusive, world-wide rights, to technology and know-how relating to very small embryonic-like stem cells. These patent applications, filed in the U.S. and abroad, relate to VSEL™ stem cell methods of isolation and treatment of disease.